The US Food and Drug Administration (FDA) approved semaglutide (Ozempic, Novo Nordisk) for reducing the risk for worsening kidney disease and cardiovascular death in adults with both type 2 diabetes ...
Ozempic has expanded beyond its original role in diabetes care to include cardiovascular and kidney protection. But with new approvals, real-world insights, and growing competition reshaping its ...
Please provide your email address to receive an email when new articles are posted on . FDA approved semaglutide to lower the risk for worsening kidney disease, kidney failure and CV death in type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback